Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study.
Malagola M, Iurlo A, Abruzzese E, Bonifacio M, Stagno F, Binotto G, D'Adda M, Lunghi M, Crugnola M, Ferrari ML, Lunghi F, Castagnetti F, Rosti G, Lemoli RM, Sancetta R, Coppi MR, Corsetti MT, Rege Cambrin G, Romano A, Tiribelli M, Russo Rossi A, Russo S, Aprile L, Bocchia M, Gandolfi L, Farina M, Bernardi S, Polverelli N, Roccaro AM, De Vivo A, Baccarani M, Russo D.
Malagola M, et al. Among authors: roccaro am.
Cancer Med. 2021 Mar;10(5):1726-1737. doi: 10.1002/cam4.3778. Epub 2021 Feb 16.
Cancer Med. 2021.
PMID: 33594821
Free PMC article.
Clinical Trial.